Distinction between MOG antibody-positive and AQP4 antibody-positive NMO spectrum disorders
DKDouglas Kazutoshi SatoDCDagoberto CallegaroMAMarco Aurélio Lana–PeixotoPWPatrick WatersFMFrederico Mennucci de Haidar Jorge
Universidade Federal de Minas Gerais
Indexed incrossrefpubmed
Abstract
Objective
To evaluate clinical features among patients with neuromyelitis optica spectrum disorders (NMOSD) who have myelin oligodendrocyte glycoprotein (MOG) antibodies, aquaporin-4 (AQP4) antibodies, or seronegativity for both antibodies.
Methods
Sera from patients diagnosed with NMOSD in 1 of 3 centers (2 sites in Brazil and 1 site in Japan) were tested for MOG and AQP4 antibodies using cell-based assays with live transfected cells.
Citation impact
843
total citations
- FWCI
- 52.63
- Percentile
- 100%
- References
- 21
Citations per year
Authors
15- DKDouglas Kazutoshi SatoCorresponding
Universidade Federal de Minas Gerais
- DCDagoberto Callegaro
Universidade Federal de Minas Gerais
- MAMarco Aurélio Lana–Peixoto
Universidade Federal de Minas Gerais
- PWPatrick Waters
Universidade Federal de Minas Gerais
- FMFrederico Mennucci de Haidar Jorge
Universidade Federal de Minas Gerais
Topics & keywords
Topics
Keywords
- Myelin oligodendrocyte glycoprotein
- Antibody
- Medicine
- Neuromyelitis optica
- Optic neuritis
- Multiple sclerosis
- Immunology
- Experimental autoimmune encephalomyelitis
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.